

# Joon-Ho Moon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8979574/publications.pdf>

Version: 2024-02-01

149  
papers

1,358  
citations

430874

18  
h-index

414414

32  
g-index

152  
all docs

152  
docs citations

152  
times ranked

2567  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. <i>Blood</i> , 2015, 126, 746-756.	1.4	160
2	Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse. <i>Blood</i> , 2018, 132, 1604-1613.	1.4	84
3	Clonal hematopoiesis is associated with risk of severe Covid-19. <i>Nature Communications</i> , 2021, 12, 5975.	12.8	81
4	COVID-19 transmission and blood transfusion: A case report. <i>Journal of Infection and Public Health</i> , 2020, 13, 1678-1679.	4.1	77
5	Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1597-1604.	2.0	76
6	Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review. <i>International Journal of Hematology</i> , 2009, 90, 383-387.	1.6	54
7	DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 61-70.	2.0	43
8	Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients. <i>Medical Oncology</i> , 2012, 29, 1179-1185.	2.5	38
9	Validation of National Institutes of Health Global Scoring System for Chronic Graft-Versus-Host Disease (GVHD) According to Overall and GVHD-Specific Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 556-563.	2.0	38
10	Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2015, 90, 1013-1020.	4.1	37
11	Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. <i>American Journal of Hematology</i> , 2017, 92, 1280-1286.	4.1	34
12	BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients. <i>Leukemia Research</i> , 2010, 34, 166-172.	0.8	31
13	Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype. <i>Haematologica</i> , 2015, 100, e351-e353.	3.5	31
14	Epidemiology and Risk Factors for Invasive Fungal Diseases among Allogeneic Hematopoietic Stem Cell Transplant Recipients in Korea: Results of a RISK Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1773-1779.	2.0	29
15	Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma. <i>BMC Cancer</i> , 2015, 15, 198.	2.6	28
16	Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment. <i>Annals of Hematology</i> , 2010, 89, 681-689.	1.8	26
17	Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant. <i>Annals of Hematology</i> , 2016, 95, 301-310.	1.8	26
18	Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype. <i>Oncotarget</i> , 2018, 9, 4961-4968.	1.8	19

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload. <i>Transfusion</i> , 2015, 55, 1613-1620.	1.6	18
20	Clinical significance of nuclear factor $\kappa$ B and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 785.	1.7	17
21	Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma. <i>Blood Research</i> , 2014, 49, 15.	1.3	16
22	Patients presenting high fever with lymphadenopathy after COVID-19 vaccination were diagnosed with hemophagocytic lymphohistiocytosis. <i>Infectious Diseases</i> , 2022, 54, 303-307.	2.8	16
23	Monosomal and complex karyotypes as prognostic parameters in patients with International Prognostic Scoring System higher risk myelodysplastic syndrome treated with azacitidine. <i>Blood Research</i> , 2014, 49, 234.	1.3	15
24	Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML. <i>Annals of Hematology</i> , 2016, 95, 625-635.	1.8	15
25	Clinical Significance of Autoantibody Expression in Allogeneic Stem-Cell Recipients. <i>Transplantation</i> , 2009, 88, 242-250.	1.0	14
26	HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1439-1450.	7.2	14
27	Induction Treatment With Cyclophosphamide, Thalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: A Phase II Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 62-67.	0.4	13
28	The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma. <i>Acta Haematologica</i> , 2018, 140, 146-156.	1.4	13
29	Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 1205-1208.	2.4	13
30	Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD. <i>Annals of Hematology</i> , 2017, 96, 805-815.	1.8	12
31	A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: <sc>ENESTK</sc>orea. <i>Cancer Medicine</i> , 2018, 7, 1814-1823.	2.8	10
32	Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 923-929.	2.0	10
33	Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing. <i>Bone Marrow Transplantation</i> , 2021, 56, 1159-1170.	2.4	10
34	Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET/CT. <i>Blood Cancer Journal</i> , 2021, 11, 190.	6.2	10
35	Clinical impact of induction treatment modalities and optimal timing of radiotherapy for the treatment of limited-stage NK/T cell lymphoma. <i>Leukemia Research</i> , 2016, 49, 80-87.	0.8	9
36	Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia. <i>Journal of Translational Medicine</i> , 2016, 14, 82.	4.4	9

#	ARTICLE	IF	CITATIONS
37	Apparent diffusion coefficient as a valuable quantitative parameter for predicting clinical outcomes in patients with newly diagnosed primary CNS lymphoma. <i>Blood Research</i> , 2020, 55, 99-106.	1.3	9
38	A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2274-2284.	6.4	8
39	Therapeutic strategies, including allogeneic stem cell transplantation, to overcome relapsed/refractory adult T-cell acute lymphoblastic leukemia. <i>Expert Review of Hematology</i> , 2021, 14, 765-775.	2.2	8
40	Genome-Wide Single-Nucleotide Polymorphism-Array Based Karyotyping Detects Clonal Aberrations Including Uniparental Disomy (UPD), Gain or Loss Which Were Unfavorable Prognostic Factor In Acute Myeloid Leukemia with Normal Karyotype.. <i>Blood</i> , 2010, 116, 1669-1669.	1.4	8
41	Clinical Outcomes and Prognostic Factors of Front-Line Autologous Stem Cell Transplantation in Patients with Extranodal NK/T-Cell Lymphoma. <i>Blood</i> , 2014, 124, 2523-2523.	1.4	8
42	Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study. <i>Annals of Hematology</i> , 2016, 95, 603-611.	1.8	7
43	Distinctive clinical characteristics and favorable outcomes in patients with large granular lymphocytosis after alloâ€‹scp>HCT</scp>: 12â€‹year followâ€‹up data. <i>European Journal of Haematology</i> , 2017, 99, 160-168.	2.2	6
44	Prognostic significance of interim PET/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era. <i>Scientific Reports</i> , 2020, 10, 11649.	3.3	6
45	RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia. <i>Scientific Reports</i> , 2020, 10, 20119.	3.3	6
46	5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 8305-8314.	1.8	6
47	A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. <i>Oncotarget</i> , 2017, 8, 37605-37618.	1.8	6
48	Outpatient-basis Chemotherapy of Oxaliplatin, 5-fluorouracil, and Leucovorin as First-line Treatment for Patients with Metastatic or Recurrent Colorectal Cancer. <i>Journal of Korean Medical Science</i> , 2007, 22, 400.	2.5	5
49	Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2013, 92, 1101-1110.	1.8	5
50	Survey of expert opinions and related recommendations regarding bridging therapy using hypomethylating agents followed by allogeneic transplantation for high-risk MDS. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 243-250.	4.4	5
51	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Monosomal Karyotypes. <i>Acta Haematologica</i> , 2015, 133, 327-335.	1.4	5
52	Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study. <i>Cancer Medicine</i> , 2017, 6, 100-108.	2.8	5
53	Which donor is better when a matched donor is not available domestically? Comparison of outcomes of allogeneic stem cell transplantation with haploidentical and international donors in a homogenous ethnic population. <i>Leukemia Research</i> , 2018, 69, 31-38.	0.8	5
54	Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 2714-2721.	1.3	5

#	ARTICLE	IF	CITATIONS
55	First Korean case of Emberger syndrome (primary lymphedema with myelodysplasia) with a novel &lt;i>&lt;sc>GATA2</sc></i> gene mutation. Korean Journal of Internal Medicine, 2016, 31, 188-190.	1.7	5
56	Prognostic Significance Of Systemic Inflammatory Factors In Patients With Diffuse Large B Cell Lymphoma Treated By R-CHOP. Blood, 2013, 122, 1802-1802.	1.4	5
57	Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast. Annals of Hematology, 2012, 91, 367-373.	1.8	4
58	Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts. Annals of Hematology, 2018, 97, 2309-2317.	1.8	4
59	Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions. Expert Review of Hematology, 2021, 14, 819-830.	2.2	4
60	Pediatric-inspired regimen with late intensification and increased dose of L-asparaginase for adult acute lymphoblastic leukemia: the KALLA 1406/1407 study. Korean Journal of Internal Medicine, 2021, 36, 1471-1485.	1.7	4
61	Clinical Significance of Autoantibody Expression in Allogeneic Stem Cell Recipients.. Blood, 2008, 112, 2205-2205.	1.4	4
62	Nilotinib Combined With Multi-Agent Chemotherapy For Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Final Results Of Prospective Multicenter Phase 2 Study. Blood, 2013, 122, 55-55.	1.4	4
63	Current status and future directions of clinical research and practice in adult acute lymphoblastic leukemia patients in Korea. Blood Research, 2014, 49, 80.	1.3	3
64	Clinical outcomes in patients with diffuse large B cell lymphoma with a partial response to first-line R-CHOP chemotherapy: prognostic value of secondary International Prognostic Index scores and Deauville scores. Annals of Hematology, 2017, 96, 1873-1881.	1.8	3
65	Highly Aggressive de novo Aleukemic Variant of Mast Cell Leukemia Without KIT D816V Mutation. Annals of Laboratory Medicine, 2017, 37, 547-549.	2.5	3
66	Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen. Yeungnam University Journal of Medicine, 2018, 35, 76-83.	1.4	3
67	Quantitative Assessment of Interim PET/CT Could Have More Prognostic Relevance than Visual Assessment for Predicting Clinical Outcome of Extranodal Diffuse Large B Cell Lymphoma. In Vivo, 2020, 34, 2127-2134.	1.3	3
68	Characterization of the novel <i><sc>DQA1</sc>*01:01:09</i> allele by next-generation sequencing. Hla, 2021, 98, 403-404.	0.6	3
69	AQP1 expression and survival in patients with colon cancer.. Journal of Clinical Oncology, 2014, 32, e14586-e14586.	1.6	3
70	Favorable Effects of Low-Dose Anti-Thymocyte Globulin in a Partially-Mismatched HLA Group in an Unrelated Allogeneic Stem Cell Transplantation Setting. Annals of Transplantation, 2015, 20, 7-15.	0.9	3
71	Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party. Oncotarget, 2017, 8, 79414-79424.	1.8	3
72	New synergistic efficacy of combination of romiplostim and steroid in refractory immune thrombocytopenia patients. Korean Journal of Internal Medicine, 2018, 33, 435-437.	1.7	3

#	ARTICLE	IF	CITATIONS
73	Clinical Effects of Hypomethylating Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome Who Received DNA-Damaging Chemotherapy for Metastatic Breast Cancer. <i>Journal of Breast Cancer</i> , 2019, 22, 647.	1.9	3
74	Clinical impact of anti-thymocyte globulin on survival and graft-versus-host disease in patients undergoing human leukocyte antigen mismatched allogeneic stem cell transplantation. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 429-437.	1.7	3
75	Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 2051-2059.	2.4	2
76	Lenalidomide as a second-line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2019, 186, e151-e155.	2.5	2
77	Utility of allogeneic hematopoietic stem cell transplantation using international donors in a homogenous ethnic population: question in the era of various alternative donors. <i>Annals of Hematology</i> , 2019, 98, 501-510.	1.8	2
78	Clinical characteristics and prognostic factors of acquired haemophilia A in Korea. <i>Haemophilia</i> , 2021, 27, e609-e616.	2.1	2
79	Genetic variations in miRNA binding site of <i>TPST1</i> and <i>ZG16B</i> associated with prognosis for patients with colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3553-3553.	1.6	2
80	Clinical Efficacy of VEL-CTD (Bortezomib, Cyclophosphamide, Thalidomide, and Dexamethasone) Regimen in Patients with Relapsed or Refractory Multiple Myeloma: A Phase II Study. <i>Blood</i> , 2008, 112, 3693-3693.	1.4	2
81	Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia. <i>Yonsei Medical Journal</i> , 2020, 61, 452.	2.2	2
82	Survey of experts on therapeutic policies and proposals for the optimal timing for allogeneic peripheral blood stem cell transplantation in transfusion-dependent patients with myelodysplastic syndrome-refractory anemia. <i>Blood Research</i> , 2016, 51, 44.	1.3	1
83	Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes. <i>Annals of Hematology</i> , 2016, 95, 1795-1804.	1.8	1
84	Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e367-e373.	0.4	1
85	Hypomethylating agent-based post-transplant strategies to maximize the outcome of high-risk acute myeloid leukemia after allogeneic stem cell transplantation. <i>Expert Review of Hematology</i> , 2020, 13, 959-969.	2.2	1
86	Optimizing Preparative Regimen for Umbilical Cord Blood Transplantation in Adult Acute Leukemia Patients: Acute Lymphoblastic Leukemia Requires Myeloablative Conditioning but Not Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2020, 9, 2310.	2.4	1
87	Clinical impact of cell-free serum Epstein-Barr virus status in patients with newly diagnosed malignant lymphoma. <i>Blood Research</i> , 2021, 56, 65-71.	1.3	1
88	Favorable Long-Term Outcomes with Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma Patients with a Positive Result On 18F-FDG PET/CT at Baseline. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, . .	0.4	1
89	Comparing Standard IPI with Revised-IPI in Patients with Diffuse Large B-Cell Lymphoma: Which Has a More Differential Potential for Predicting the Outcomes after R-CHOP Chemotherapy.. <i>Blood</i> , 2008, 112, 2003-2003.	1.4	1
90	Immunoglobulin D Multiple Myeloma: Clinical Presentation, Response to Therapy and Prognostic Factors in 75 Patients; An Analysis of the Korean Multiple Myeloma Working Party (KMMWP).. <i>Blood</i> , 2009, 114, 1792-1792.	1.4	1

#	ARTICLE	IF	CITATIONS
91	Candidate Pathway Approach of Single Nucleotide Polymorphism On Imatinib Transport/Metabolism Pathway and DNA Repair Enzyme Pathway Associated with Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia.. Blood, 2009, 114, 3284-3284.	1.4	1
92	Impact of ATG on New HLA Groups for Unrelated Donor Allogeneic Stem Cell Transplantation. Blood, 2011, 118, 3017-3017.	1.4	1
93	Lenalidomide As a Second-Line Therapy after Failure of Hypomethylating Agents in Patients with Myelodysplastic Syndrome. Blood, 2015, 126, 1687-1687.	1.4	1
94	No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome. Korean Journal of Internal Medicine, 2018, 33, 1194-1202.	1.7	1
95	Clinical impact of spine magnetic resonance imaging as a valuable prognostic tool for patients with multiple myeloma: a retrospective study. , 2022, 39, 300-308.		1
96	Impact of Consolidation Cycles Before Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e529-e535.	0.4	0
97	Favorable long-term survival using consolidation chemotherapy without allogeneic hematopoietic cell transplantation for acute myeloid leukemia with wild-type <i>NPM1</i> without <i>FLT3</i> -ITD. Blood Research, 2019, 54, 189-197.	1.3	0
98	Prognostic impact of 18F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment. International Journal of Hematology, 2021, 113, 668-674.	1.6	0
99	Variable Number of Tandem Repeats (VNTR) Disparity between Donor and Recipient has a Potential to Predict the Outcomes of HLA-identical Allogeneic Stem Cell Transplantation. The Korean Journal of Hematology, 2005, 40, 231.	0.7	0
100	Rapid Helper T-Cell Recovery at 3 Months Correlates to Successful Transplant Outcomes after Allogeneic Stem Cell Transplantation.. Blood, 2005, 106, 5201-5201.	1.4	0
101	Variable Number of Tandem Repeat (VNTR) Disparity between Donor and Recipient Has Potential To Predict Outcomes of HLA-Identical Allogeneic Stem Cell Transplantation.. Blood, 2005, 106, 5202-5202.	1.4	0
102	Risk Factors for Predicting CMV Infection in Allogeneic-PBSCT Setting: MNC Dose, Campath Use, and Acute GVHD Grade $\geq 2$ .. Blood, 2006, 108, 5298-5298.	1.4	0
103	Treatment Outcomes for Imatinib Mesylate and Allogeneic Stem Cell Transplantation in Patients with CML Based on RQ-PCR, and the Efficacy of Dose Escalation of Imatinib Mesylate in Patients with Cytogenetic or Hematologic Resistance.. Blood, 2006, 108, 4762-4762.	1.4	0
104	The Impact of Alemtuzumab as a Component of Conditioning Regimens on Transplantation Outcomes in a Setting of CMV-Seropositive Recipient and Donor.. Blood, 2006, 108, 5270-5270.	1.4	0
105	Retrospective Analysis of Post-Remission Modalities in AML Patients with Normal Karyotype.. Blood, 2007, 110, 4258-4258.	1.4	0
106	The Mobilization Effects of G-CSF, GM-CSF and Darbepoetin- $\alpha$ for Allogeneic Peripheral Blood Stem Cell Transplantation.. Blood, 2007, 110, 4932-4932.	1.4	0
107	Early Onset of Acute Graft-Versus-Host Disease Indicating a Worse Prognosis in Terms of Chronic Graft-Versus-Host Disease and Survival Compared to Late Onset.. Blood, 2007, 110, 4979-4979.	1.4	0
108	BCL2 Gene Polymorphism Could Predict the Treatment Outcomes in Patients with De Novo Acute Myeloid Leukemia. Blood, 2008, 112, 3973-3973.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Infectious Complications in Asian Patients Treated with Alemtuzumab: Results From a Multicenter Study.. Blood, 2009, 114, 5009-5009.	1.4	0
110	Favorable Transplantation Outcomes Associated with Early Recovery of Lymphocytes and CD8+ Cells Following Allogeneic Stem Cell Transplantation.. Blood, 2009, 114, 4665-4665.	1.4	0
111	Comparative Analysis of Outcomes of Allogeneic Peripheral Blood Stem Cell Transplantation From Related and Unrelated Donors.. Blood, 2009, 114, 3381-3381.	1.4	0
112	Multicenter Retrospective Analysis of Second Allogeneic HSCT Outcomes for Hematologic Malignancies in Korea.. Blood, 2009, 114, 4298-4298.	1.4	0
113	Clinical Implications of Pulmonary Function Tests in Allogeneic Stem Cell Recipients.. Blood, 2009, 114, 4297-4297.	1.4	0
114	Genome-Wide Single-Nucleotide Polymorphism-Array Based Karyotyping Detects Clonal Aberrations, and Predicts the Risk of Imatinib Failure In Chronic Myeloid Leukemia.. Blood, 2010, 116, 3387-3387.	1.4	0
115	Trough Plasma Imatinib Levels and ABCG2 Polymorphisms Are Correlated with Optimal Cytogenetic Responses at 6 Months After Treatment with Standard Dose of Imatinib In Newly Diagnosed CML. Blood, 2010, 116, 2272-2272.	1.4	0
116	Pharmacogenomics-Based Drug Response Prediction Model for Acute Myeloid Leukemia with Normal Karyotype. Blood, 2010, 116, 2698-2698.	1.4	0
117	Clinical Efficacy of a Bortezomib, Cyclophosphamide and Dexamethasone Compared with Bortezomib, Cyclophosphamide, Thalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. Blood, 2011, 118, 1868-1868.	1.4	0
118	Genome-Wide Single-Nucleotide Polymorphism-Array Can Improve Prognostic Stratification of Core Binding Factor Acute Myeloid Leukemia, Especially in the Subgroup with Inv(16)/t(16;16) or without D816 C-KIT Mutation,. Blood, 2011, 118, 3515-3515.	1.4	0
119	Bortezomib Induction Followed by ASCT in Patients with Multiple Myeloma: Achievement of Response After Induction and Achieving CR Post-ASCT Are Both Important Prognostic Markers. Blood, 2011, 118, 1866-1866.	1.4	0
120	Prognostic impact of miR-146 polymorphism in patients with resected colorectal cancer.. Journal of Clinical Oncology, 2012, 30, 3554-3554.	1.6	0
121	The outcomes of allogeneic stem cell transplantation in AML patients with monosomal karyotypes.. Journal of Clinical Oncology, 2012, 30, 6538-6538.	1.6	0
122	Clinical significance of nuclear kappa B and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma.. Journal of Clinical Oncology, 2012, 30, e18533-e18533.	1.6	0
123	Impact of ATG on new HLA groups for unrelated donor allogeneic stem cell transplantation.. Journal of Clinical Oncology, 2012, 30, 6536-6536.	1.6	0
124	Independent Validation of Chronic Graft-Versus-Host Disease (GVHD) Grading System Proposed by the NIH Consensus Criteria in Terms of Prognostic Stratification of the Patients Developed Chronic Gvhd. Blood, 2012, 120, 1946-1946.	1.4	0
125	Prognostic Power of Chronic Gvhd Risk Score Model by Ibmtr Can Be Improved with Addition of Absolute Lymphocyte Counts and Eosinophil Counts At the Onset of Chronic Gvhd. Blood, 2012, 120, 4184-4184.	1.4	0
126	Genome-Wide Genotype-Based Risk Model for Survival in Acute Myeloid Leukemia Patients with Normal Karyotype.. Blood, 2012, 120, 2526-2526.	1.4	0



#	ARTICLE	IF	CITATIONS
127	Whole Exome Sequencing Analysis in AML with Normal Karyotype Not Harboring FLT3/ITD Mutation Reveals Novel Genetic Alterations.. Blood, 2012, 120, 2593-2593.	1.4	0
128	NPM1, IDH1/2 and DNAM1 Gene Mutations Can Improve a Prognostic Stratification of Acute Myeloid Leukemia Patients with Normal Karyotype but Not Harboring FLT3/ITD Mutation.. Blood, 2012, 120, 2534-2534.	1.4	0
129	Predictive Factors for Rapid Engraftment of Neutrophil and Platelet After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with Hematologic Malignancies. Blood, 2012, 120, 4499-4499.	1.4	0
130	Different Characteristics Identified by Single Nucleotide Polymorphism Array Analysis in Leukemia Suggest the Need for Different Application Strategies Depending On Disease Category.. Blood, 2012, 120, 2490-2490.	1.4	0
131	Clinical Efficacy of Mitoxantrone-Based Salvage Chemotherapy in Adult Patients with Relapsed or Refractory ALL; Retrospective Multicenter Study of Korean Adult ALL Working Party. Blood, 2012, 120, 4306-4306.	1.4	0
132	Flow Cytometric Osmotic Fragility Test; A Sensitive and Quantitative Diagnostic Approach for Hereditary Spherocytosis. Blood, 2012, 120, 5151-5151.	1.4	0
133	Impact of antithymocyte globulin on new HLA groups for unrelated donor allogeneic stem cell transplantation.. Journal of Clinical Oncology, 2013, 31, e18017-e18017.	1.6	0
134	Steroid Failure At Day 28 After Acute Graft-Versus-Host Disease Treatment and Long-Term Outcomes Following Allogeneic Transplantation: Adverse Impact On Survival and Non-Relapse Mortality But No Increasing Risk Of Relapse. Blood, 2013, 122, 2066-2066.	1.4	0
135	Role Of Hypomethylating Agents For Patients With Lower-Risk Myelodysplastic Syndrome Defined By IPSS and IPSS-R. Blood, 2013, 122, 2782-2782.	1.4	0
136	An Adverse Prognostic Effect of Homozygous TET2 Mutational Status on the Relapse Risk of Acute Myeloid Leukemia Patients of Normal Karyotype. Blood, 2014, 124, 1052-1052.	1.4	0
137	Efficacy and Safety of Deferasirox Estimated By Serum Ferritin and Labile Plasma Iron Levels in Patients with Aplastic Anemia, Myelodysplastic Syndrome, or Hematologic Malignancy with Transfusional Iron Overload. Blood, 2014, 124, 2676-2676.	1.4	0
138	Inferior Long-Term Outcome of Front-Line Hypomethylating Agent Compared to Supportive Care in Patients with Lower Risk Myelodysplastic Syndrome: Prosensity Score Matched Analysis. Blood, 2014, 124, 3255-3255.	1.4	0
139	Long-Term Follow-up of Continuous Imatinib Plus Combination Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3654-3654.	1.4	0
140	Clinical significance of radiotherapy in the treatment of limited stage NK/T cell lymphoma.. Journal of Clinical Oncology, 2015, 33, 8549-8549.	1.6	0
141	5-Hydroxymethylcytosine Is Correlated with TET2 or IDH1/2 Mutations However, May Not be a Prognostic Value to Predict the Survivals in Normal Karyotype AML. Blood, 2015, 126, 3832-3832.	1.4	0
142	Discrepancy of Interim PET/CT Responses Based on Visual and Quantitative SUV-Based Assessments in the Patients with Diffuse Large B-Cell Lymphoma and Extranodal Involvements. Blood, 2015, 126, 1446-1446.	1.4	0
143	Replication of New Genomic Classification System in Acute Myeloid Leukemia with Normal Karyotype. Blood, 2016, 128, 2876-2876.	1.4	0
144	High Residual Allelic Burden Increases Leukemic Transformation Irrespective of Clinical Response in Patients with Lower Risk Myelodysplastic Syndrome Treated with Azacitidine. Blood, 2019, 134, 4263-4263.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Clinical Impact of 18f-FDG PET/CT As a Valuable Prognostic Tool for the Newly Diagnosed Multiple Myeloma with Extramedullary Disease. <i>Blood</i> , 2019, 134, 3142-3142.	1.4	0
146	Apparent diffusion coefficient as a valuable quantitative parameter for predicting clinical outcomes in patients with newly diagnosed primary CNS lymphoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e14532-e14532.	1.6	0
147	Development of a New Risk Stratification System for Patients with Newly Diagnosed Multiple Myeloma Using R-ISS and 18F-FDG PET/CT. <i>Blood</i> , 2021, 138, 3757-3757.	1.4	0
148	Multicenter Phase II Study to Evaluate Therapeutic Efficacy of Imatinib Mesylate in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2021, 138, 2889-2889.	1.4	0
149	Light and shade of ruxolitinib: positive role of early treatment with ruxolitinib and ruxolitinib withdrawal syndrome in patients with myelofibrosis. <i>Expert Review of Hematology</i> , 0, , 1-9.	2.2	0